Overview

A Study Assessing the Long-Term Safety and Tolerability of FHTR2163 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Status:
Recruiting
Trial end date:
2025-12-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the long-term safety and tolerability of intravitreal (ITV) injections of FHTR2163 administered every 4 weeks (Q4W) or every 8 weeks (Q8W) in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) who completed the parent study (NCT03972709/GR40973).
Phase:
Phase 2
Details
Lead Sponsor:
Genentech, Inc.